Randomized designs for early trials of new cancer treatments - An overview

Drug Information Journal

Volumn 34, Issue 2, 2000, Pages 387-396

  Buyse, Marc ^a,b  

^a INTERNATIONAL DRUG DEVELOPMENT INSTITUTE   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Cancer treatments; Phase II trials; Randomization

Indexed keywords

CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESEARCH; METHODOLOGY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; STATISTICAL ANALYSIS;

EID: 0034120101     PISSN: 00928615     EISSN: None     Source Type: Journal    
DOI: 10.1177/009286150003400207     Document Type: Review

References (33)

1. Ratain MJ, Mick R, Schilsky RL, Siegler M. Statistical and ethical issues in the design and conduct of Phase I and II clinical trials of new anticancer agents. J Natl Cancer Instit. 1993;85:1637-1643.
2. Storer B, DeMets D. Current Phase I/II designs: are they adequate? J Clin Research and Drug Dev. 1987; 1:121-130.
3. Mick R, Lane N, Faugherty C, Ratain MJ. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in Phase I cancer trials. J Natl Cancer Instit. 1994;86:1685-1693.
4. Durham SD, Flournoy N, Rosenberger WF. A random walk rule for Phase I clinical trials. Biometrics. 1997:53:745-760.
5. Marsoni S, Hoth D, Simon R, Leyland-Jones B, De Rosa M, Wittes RE. Clinical drug development: an analysis of Phase II trials, 1970-1985. Cancer Treat Rep. 1987;71:71-80.
6. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48, Geneva: World Health Organization; 1979.
7. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chron Dis. 1961; 13:346-353.
8. Fleming TR. One-sample multiple testing procedures for Phase II clinical trials. Biometrics. 1982; 38:143-151.
9. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
10. Pouillart P, Fumoleau P, Romieu G, et al. Final results of a Phase II randomized, parallel study of doxorubicin/cyclophosphamide (AC) and doxorubicin/taxol (paclitaxel) (AT) as neoadjuvant treatment of local-regional breast cancer. Proc ASCO. 1999; 18:73a (Abstract #275).
11. Herson J. Statistical aspects in design and analysis of Phase II clinical trials. In: Buyse ME, Staquet MJ, Sylvester RJ (eds), Cancer Clinical Trials. Methods and Practice. Oxford: Oxford University Press; 1985: pp 239-257.
12. Moertel CG, Schutt AJ, Hahn RG, Reitemeier RS. Effects of patient selection on results of Phase II chemotherapy trials in gastrointestinal cancer. Cancer Chemother Rep. 1974;58:257-260.
13. Piedbois P, Buyse M, Pignon JP. Critical issues in colorectal cancer trial design. In: Management of Colorectal Cancer. H Bleiberg, P Rougier, HJ Wilke, eds. London: Martin Dunitz Publishers; 1997:375-386.
14. Wadler S, Schwartz EL, Goldman M, et al. Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol. 1995;7:1769-1775.
15. Raderer M, Scheithauer W. Treatment of advanced colorectal cancer with 5-fluorouracil and interferon-α: an overview of clinical trials. Eur J Cancer. 1995; 31A:1002-1008.
16. Greco FA, Figlin R, York M, et al. Phase III randomized study to compare interferon alfa-2a in combination with fluorouracil versus fluorouracil alone in patients with advanced colorectal cancer. J Clin Oncol. 1996;10:2674-2681.
17. Corfu-A Study Group. Phase III randomized study of two flouorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol. 1995;13:921-928.
18. Gehan EA, Freireich EJ. Non-randomized controls in cancer trials. N Engl J Med. 1974;290:198-203.
19. Simon R, Wittes RE, Ellenberg SS. Randomized Phase II clinical trials. Cancer Treat Rep. 1985;69: 1375-1381.
20. Fisher B, Rockette H, Robidoux A, et al. Effect of preoperative therapy for breast cancer on locoregional disease: first report of NSABP-18. Proc ASCO. 1994;13:64 (Abstract 57).
21. Liu PY, LeBlanc M, Desai M. False positive rates of randomized Phase II designs. Control Clin Trials. 1999;20:343-352.
22. Herson J, Carter SK. Calibrated Phase II clinical trials in oncology. Stat Med. 1986;5:441-447.
23. Leichman CG, Fleming TR, Muggia FM, et al. Phase I study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group Study. J Clin Oncol. 1995;13:1303-1311.
24. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of 5-fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992;10:896-903.
25. Meta-Analysis Group In Cancer. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol. 1998;16:301-308.
26. Royal RM. Ethics and statistics in randomized clinical trials (with discussion). Stat Science. 1991;6: 52-88.
27. Chalmers TC. Symposium on diseases of the liver: randomization of the first patient. Med Clin N Am. 1975;59:1035-1037.
28. Chalmers I. Report of meeting of open section. J Royal Soc Med. 1990;83:337-339.
29. Buyse M. Potential and pitfalls of randomized clinical trials in cancer research. Cancer Surveys. 1989; 8:91-105.
30. Kalish LA, Begg CB. Treatment allocation methods in clinical trials: a review. Stat Med. 1985;4:129-144.
31. Simon R. Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep. 1984;68:185-192.
32. Therneau TM. How many stratification factors are "too many" to use in a randomization plan? Control Clin Trials. 1993;14:98-108.
33. Pocock SJ, Simon R: Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics. 1975;31:103-115.